Literature DB >> 21833615

Successful oral desensitization to i.v. para-aminosalicylic acid (PAS) using encapsulated PAS dry substance.

S M Vesenbeckh1, J Becker, C Huhnt, B Karras, T T Bauer, H Mauch, H Rüssmann, N Schönfeld.   

Abstract

INTRODUCTION: para-Aminosalicylic acid (PAS) is commonly used in the treatment of drug-resistant tuberculosis, including multidrug-resistant tuberculosis. Since its first use in the 1940s, hypersensitivity reactions frequently limit its use in clinical practice. Cases of successful desensitization against PAS using orally administered ascending doses are described in the literature. CASE REPORT: A 25-year-old patient with severe pulmonary multidrug-resistant tuberculosis developed drug fever with rash, acral cyanosis, and shivering immediately after the intravenous application of PAS. Hard gelatine capsules containing PAS dry substance were prepared in order to desensitize this patient. Encapsulated PAS was applied orally in rising doses starting with 10 mg/day and doubling the dose every 2 days until the half-maximal dose of 5,120 mg was reached. Desensitization covers a period of 21 days. Subsequent intravenous application of PAS at the full dose was well tolerated. In a 12-month follow-up period, no more allergic reactions appeared.
CONCLUSIONS: PAS dry substance encapsulated in hard gelatine capsules and administered orally in rising concentrations may be useful to archive a successful desensitization for subsequent intravenous applications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21833615     DOI: 10.1007/s15010-011-0172-y

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  9 in total

1.  [Guidelines for drug treatment of tuberculosis in adults and childhood].

Authors:  T Schaberg; M Forssbohm; B Hauer; D Kirsten; R Kropp; R Loddenkemper; K Magdorf; H Rieder; D Sagebiel; R Urbanczik
Journal:  Pneumologie       Date:  2001-11

2.  Isoniazid and para-aminosalicylic acid toxicity in 513 cases: a study including high doses of INH and gastrointestinal intolerance to PAS.

Authors:  S J BERTE; H J DEWLETT
Journal:  Dis Chest       Date:  1959-08

3.  ISONIAZID, PARA-AMINOSALICYLIC ACID, AND STREPTOMYCIN INTOLERANCE IN 1,744 PATIENTS. AN ANALYSIS OF REACTIONS TO SINGLE DRUGS AND DRUG GROUPS PLUS DATA ON MULTIPLE REACTIONS, TYPE AND TIME OF REACTIONS, AND DESENSITIZATION.

Authors:  S J BERTE; J D DIMASE; C S CHRISTIANSON
Journal:  Am Rev Respir Dis       Date:  1964-10

4.  The use of corticotrophin in rapid desensitization to PAS.

Authors:  R S FRANCIS; S K GUPTA
Journal:  Tubercle       Date:  1958-08

5.  Short-term ACTH therapy for desensitisation against anti-tuberculosis drugs.

Authors:  S K GUPTA; H D PALMER
Journal:  Br J Dis Chest       Date:  1959-04

6.  Combined corticotrophin therapy and chemotherapy in pulmonary tuberculosis, with special reference to hypersensitive reactions.

Authors:  L E HOUGHTON
Journal:  Lancet       Date:  1954-03-20       Impact factor: 79.321

7.  Desensitization to streptomycin and P.A.S.

Authors:  J CROFTON
Journal:  Br Med J       Date:  1953-11-07

8.  Para-aminosalicylic acid (PAS) desensitization review in a case of multidrug-resistant pulmonary tuberculosis.

Authors:  J W Wilson; P Kelkar; E Frigas
Journal:  Int J Tuberc Lung Dis       Date:  2003-05       Impact factor: 2.373

9.  Drug fever.

Authors:  B A Lipsky; J V Hirschmann
Journal:  JAMA       Date:  1981-02-27       Impact factor: 56.272

  9 in total
  1 in total

1.  Antimycobacterial, antimicrobial, and biocompatibility properties of para-aminosalicylic acid with zinc layered hydroxide and Zn/Al layered double hydroxide nanocomposites.

Authors:  Bullo Saifullah; Mohamed E El Zowalaty; Palanisamy Arulselvan; Sharida Fakurazi; Thomas J Webster; Benjamin M Geilich; Mohd Zobir Hussein
Journal:  Drug Des Devel Ther       Date:  2014-07-28       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.